Validation of a novel ELISA for measurement of MDA-LDL in human plasma

Free Radical Biology and Medicine

Volumn 35, Issue 5, 2003, Pages 517-527

  Bevan, Ruth J ^a   Durand, Mireille F ^a   Hickenbotham, Peter T ^a   Kitas, George D ^b,c   Patel, Parul R ^a   Podmore, Ian D ^d   Griffiths, Helen R ^e   Waller, Helen L ^a   Lunec, Joseph ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF SALFORD   (United Kingdom)

^e ASTON UNIVERSITY   (United Kingdom)

Author keywords

Antibodies; ELISA; F2 isoprostanes; Free radicals; GC MS; HPLC; MDA; MDA LDL; Plasma

Indexed keywords

APOLIPOPROTEIN B100; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

EID: 0142043463     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(03)00359-9     Document Type: Article

References (26)

1. Halliwell B., Gutteridge J.M.C. Role of free radicals and catalytic metal ions in human disease: an overview. Packer L., Glazer A.N. Methods in enzymology. 1990;1-85 Academic Press, London.
2. Moore K., Roberts L.J. Measurement of lipid peroxidation. Free Radic. Res. 28:1998;659-671.
3. Palanski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Pathasarathy S., Carew T.E., Steinberg D., Witzum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1989;1372-1376.
4. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Whitzum J.L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity . N. Engl. J. Med. 320:1989;915-924.
5. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76:1979;333-337.
6. Griffiths H.R., Lunec J. A pathologist's prognosis for Redox reaction profiles. Redox Rep. 2:1996;85-87.
7. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease how should we move forward? Cardiovasc. Res. 47:2000;410-418.
8. Gutteridge J.M.C. Aspects to consider when detecting and measuring lipid peroxidation. Free Radic. Res. Commun. 1:1986;173-184.
9. Young I.S., Trimble E.R. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann. Clin. Biochem. 28:1991;504-508.
10. de Zwart L.L., Meerman J.H.N., Commandeur J.N.M., Vermeulen N.P.E. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic. Biol. Med. 26:1999;202-206.
11. 2-isoprostanes in human urine. Proc. Natl. Acad. Sci. USA. 96:1999;13381-13386.
12. Morrow J.D., Roberts L.J. The isoprostanes current knowledge and directions for future research . Biochem. Pharamacol. 51:1996;1-9.
13. Chen Q., Esterbauer H., Jurgens G. Studies on epitopes on low density lipoprotein modified by 4-hydroxynonenal biochemical characterisation and determination . Biochem. J. 288:1992;249-254.
14. Salonen J., Yla-Herttuala A., Yamamoto R., Butler S.W., Korpela H., Salonen R., Nyyssonen K., Palanski W., Witzum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
15. Maggi E., Finardi G., Poli M., Bollati P., Filipponi M., Stefano G., Paolini G., Grossi A., Clot P., Albano E., Bellomo G. Specificity of autoantibodies against oxidised LDL as an additional marker for atherosclerotic risk. Coron. Artery Dis. 4:1993;1119-1122.
16. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1955;1345-1353.
17. Fogleman A.M., Ishaiahu S., Seager J., Hokom M., Child J.S., Edwards P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl. Acad. Sci. USA. 77:1980;2214-2218.
18. Harlow E., Lane D. Antibodies: a laboratory manual. 1988;Cold Spring Harbor Laboratory, Cold Spring, NY.
19. 2-ethenodeoxyguanosine as a potential marker for DNA adduct formation by trans-4-hydroxy-2-nonenal. Cancer Res. 48:1988;320-323.
20. Murata-Kamiya N., Kamiya H., Iwamoto N., Kasai H. Formation of a mutagen, glyoxal, from DNA treated with oxygen free radicals. Carcinogenesis. 16:1995;2251-2253.
21. 2-propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. Cancer Res. 44:1984;990-995.
22. 2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry development of a solid-phase extraction procedure . J. Chromatogr. B Biomed. Sci. Appl. 667:1999;199-208.
23. 2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Packer L. Methods in enzymology. 1999;3-12 Academic Press, London.
24. Shoukry M.I., Gong E.L., Nichols A.V. Apolipoprotein-lipid association in oxidatively modified HDL and LDL. Biochim. Biophys. Acta. 1210:1994;355-360.
25. Decossin C., Tailleux A., Fruchart J.-C., Fievet C. Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction. Biochim. Biophys. Acta. 1255:1995;31-38.
26. Lee M.-J., Chou F.-P., Tseng T.-H., Hsieh M.-H., Lin M.-C., Wang C.-J. Hibiscus protocatechuic acid or esculetin can inhibit oxidative LDL induced by either copper ion or nitric oxide donor. J. Agric. Food Chem. 50:2002;2130-2136.